[go: up one dir, main page]

WO1992019234A3 - Methode de traitement/prevention de l'usage de drogue - Google Patents

Methode de traitement/prevention de l'usage de drogue Download PDF

Info

Publication number
WO1992019234A3
WO1992019234A3 PCT/US1992/002808 US9202808W WO9219234A3 WO 1992019234 A3 WO1992019234 A3 WO 1992019234A3 US 9202808 W US9202808 W US 9202808W WO 9219234 A3 WO9219234 A3 WO 9219234A3
Authority
WO
WIPO (PCT)
Prior art keywords
dependent
substance
individual
treating
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1992/002808
Other languages
English (en)
Other versions
WO1992019234A2 (fr
Inventor
Montford F Piercey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Priority to JP4511382A priority Critical patent/JPH06506951A/ja
Publication of WO1992019234A2 publication Critical patent/WO1992019234A2/fr
Publication of WO1992019234A3 publication Critical patent/WO1992019234A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Méthode destinée à soigner l'être humain qui est ou était dépendant d'une drogue. Elle consiste à administrer à l'individu une quantité effective d'une aminotétraline de la formule (I). Soigner, c'est 1) traiter un individu qui est dépendant (soit physiquement, soit psychologiquement) d'une drogue; 2) empêcher un individu qui prend une drogue pour se distraire, mais n'en est pas dépendant, de devenir dépendant de la même drogue ou d'autres drogues; 3) empêcher un individu qui était par le passé, mais ne l'est plus, dépendant d'une drogue, de le redevenir; 4) prévenir la dépendance de la drogue d'individus qui n'ont jamais consommé de la drogue, mais dont les modes de vie et activités laissent croire aux médecins qu'ils risquent de prendre une drogue à des fins de distraction et/ou de devenir dépendants de différentes drogues.
PCT/US1992/002808 1991-04-26 1992-04-13 Methode de traitement/prevention de l'usage de drogue Ceased WO1992019234A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP4511382A JPH06506951A (ja) 1991-04-26 1992-04-13 物質乱用の治療／予防方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69323891A 1991-04-26 1991-04-26
US693,238 1991-04-26

Publications (2)

Publication Number Publication Date
WO1992019234A2 WO1992019234A2 (fr) 1992-11-12
WO1992019234A3 true WO1992019234A3 (fr) 1993-01-07

Family

ID=24783880

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/002808 Ceased WO1992019234A2 (fr) 1991-04-26 1992-04-13 Methode de traitement/prevention de l'usage de drogue

Country Status (5)

Country Link
EP (1) EP0581865A1 (fr)
JP (1) JPH06506951A (fr)
AU (1) AU1915192A (fr)
CA (1) CA2106197A1 (fr)
WO (1) WO1992019234A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009121872A2 (fr) 2008-04-01 2009-10-08 Abbott Gmbh & Co. Kg Tétrahydroisoquinoléines, compositions pharmaceutiques les contenant et leur utilisation en thérapie
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
JP2014521682A (ja) 2011-08-05 2014-08-28 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミノクロマン、アミノチオクロマンおよびアミノ−１，２，３，４−テトラヒドロキノリン誘導体、これらを含有する医薬組成物、ならびに治療におけるこれらの使用
CA2853254A1 (fr) 2011-11-18 2013-05-23 Abbvie Inc. Derives aminobenzocycloheptene, aminotetraline, aminoindane et phenalkylamine n-substitues, composition pharmaceutiques les contenant, et leur application therapeutique
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
KR20160062165A (ko) 2013-10-17 2016-06-01 아비에 도이치란트 게엠베하 운트 콤파니 카게 아미노테트랄린 및 아미노인단 유도체, 이들을 포함하는 약제학적 조성물, 및 치료에서 이들의 용도
CN105992764A (zh) 2013-10-17 2016-10-05 艾伯维德国有限责任两合公司 氨基色满、氨基硫代色满及氨基-1,2,3,4-四氢喹啉衍生物，包含其的药物组合物及其在治疗中的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0064964A1 (fr) * 1981-05-08 1982-11-17 Astra Läkemedel Aktiebolag 1-Alcoyl-2-aminotétralines thérapeutiquement utiles
US4800204A (en) * 1987-05-07 1989-01-24 Mueller Peter S Method of controlling tobacco use
US4935429A (en) * 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
US4994486A (en) * 1989-05-31 1991-02-19 Abbott Laboratories Dopaminergic compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0064964A1 (fr) * 1981-05-08 1982-11-17 Astra Läkemedel Aktiebolag 1-Alcoyl-2-aminotétralines thérapeutiquement utiles
US4935429A (en) * 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
US4800204A (en) * 1987-05-07 1989-01-24 Mueller Peter S Method of controlling tobacco use
US4994486A (en) * 1989-05-31 1991-02-19 Abbott Laboratories Dopaminergic compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Alcohol, vol. 7, no. 3, May/June 1990, Pergamon Press plc, (US), G.F. KOOB et al.: "Pharmacology of drug self-administration", pages 193-197, see page 195 *
European Journal of Pharmacology, vol. 182, no. 2, 3 July 1990, Elsevier Science Publishers B.V. (Biomedical Division), M.F. PIERCEY et al.: "Electrophysiological effects of dopamine autoreceptor antagonists, (+)-AJ 76 and (+)-UH 232", pages 219-226, see whole document *
J. Med. Chem., vol. 25, no. 3, 1982, American Chemical Society, D.S. FRIES et al.: "Aminotetralins as narcotic antagonists. 2. Synthesis and opiate-related activity of 1-phenyl-3-aminotetralins", pages 216-220, see whole document *
Journal of Neural Transmission, vol. 65, no. 1, 1986, Springer-Verlag, K. SVENSSON et al.: "(+)-UH 232 and (+)-UH 242: novel stereoselective dopamine receptor antagonists with preferential action on autoreceptors", pages 1-27, see whole document *
Psychopharmacology, vol. 107, no. 1, May 1992, Springer-Verlag, (Berlin, DE), P.M. CALLAHAN et al.: "Effects of the putative dopamine autoreceptor antagonists (+)-AJ 76 and (+)-UH 232 on the discriminative stimulus properties of cocaine", pages 73-77, see whole document *

Also Published As

Publication number Publication date
EP0581865A1 (fr) 1994-02-09
AU1915192A (en) 1992-12-21
CA2106197A1 (fr) 1992-10-27
WO1992019234A2 (fr) 1992-11-12
JPH06506951A (ja) 1994-08-04

Similar Documents

Publication Publication Date Title
WO1992019234A3 (fr) Methode de traitement/prevention de l'usage de drogue
CA2231803A1 (fr) Extrait lipidique possedant une activite anti-inflammatoire
GB9519661D0 (en) Fatty acid treatment
AU674894B2 (en) Treatment of conditions and disease
AU8138687A (en) Agents for combating pests and plant treatment agents
CA2332406A1 (fr) Traitement de troubles et de maladies neuromusculaires a l'aide de differents serotypes de botulinum
OA09194A (en) "Insecticidal treatment and compositions therefor".
FR2600900B1 (fr) Dispositif de protection et/ou de maintien d'une partie d'un corps humain ou animal, notamment les jambes d'un joueur de football, et procede de realisation d'un tel dispositif
Kemp Model-based monitoring of human sleep stages
AU639097B2 (en) Medicament for treating hyperlipidaemia and/or atherosclerosis
EP0328924A3 (fr) Composés de thiénotriazolodiazépine et ses applications pharmaceutiques
AU3861989A (en) Method for the treatment and the diagnosis of coronary heart disease
EP0744176A3 (fr) Médicaments pour inhiber les pertes osseuses
AU1926188A (en) N-benzoyl-n'-2,5-dihalo-4-perfluoroalkoxyphenylureas, their preparation and use in the control of pests
AU623165B2 (en) Method of inhibiting the spread of disease and infection in structures
EP0207505A3 (fr) Utilisation d'un prényl cétone dans la préparation d'un médicament contre la gastrite
ZA924128B (en) New combination preparations for treatment of Parkinson's disease.
EP0286802A3 (fr) Emploi de l'ofloxacine pour le traitement ou la prophylaxie topique des troubles péridontiques
AU3881889A (en) Human interferon-gamma, process to prepare said human interferon-gamma, and its use
EP0343832A3 (fr) Composés de 5H-pyrazolo(4,3-a)quinolizin-5-one aux activités thérapeutiques
DE69834404D1 (de) Antimutagenmittel
AU1162788A (en) Oxime-ethers of 2,6-dioxobicyclo-(3.3.0)octanones for treatment of heart and circulation diseases
裘雪亭 TREATMENT OF PERI-PARTURITION CHLOASMA
Tissenbaum The effect of partial denerbation on the anterior tibialis motoneuron pool of normal (C57BL/6J) and dystrophic (dy2j/dy2j) mice.
World Health Organization Control of pneumoconiosis: prevention, early diagnosis and treatment, report prepared by a WHO consultation, Geneva, 1-3 November 1989

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MN MW NO PL RO RU SD US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MN MW NO PL RO RU SD US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1992911383

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2106197

Country of ref document: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1992911383

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992911383

Country of ref document: EP